{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T03:52:00Z","timestamp":1780113120317,"version":"3.54.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.schres.2024.08.018","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T04:01:46Z","timestamp":1724904106000},"page":"104-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The timing and severity of clozapine-associated neutropenia in the US: Is the risk overstated?"],"prefix":"10.1016","volume":"272","author":[{"given":"Allison S.","family":"Brandt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Frederick C.","family":"Nucifora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Zandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell L.","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2024.08.018_bb0005","series-title":"Racial Disparities in Clozapine Prescription Patterns Among Patients With Schizophrenia. PS appi.ps.20230226","author":"Barry","year":"2024"},{"key":"10.1016\/j.schres.2024.08.018_bb0010","unstructured":"Clozapine REMS, 2021. Clozapine and the Risk of Neutropenia: A Guide for Healthcare Providers. https:\/\/cpmgstorageproduction.blob.core.windows.net\/cpmg-public\/cpmg-hpguide-clozapine-prescriber-guide%20v0_05%20clean.pdf?skoid=153f69fb-5a75-4401-8fda-28b1bd974fd0&sktid=59fc620e-de8c-4745-abcc-18182d1bf20e&skt=2024-04-25T19%3A47%3A31Z&ske=2024-05-01T19%3A52%3A31Z&sks=b&skv=2021-12-02&sv=2021-12-02&st=2021-08-10T13%3A51%3A35Z&se=2031-08-10T23%3A59%3A59Z&sr=b&sp=rc&sig=%2FSookZ4ygjZlxEsNBxEIyCGqVFpmfhqTYPvkPlkAZfs%3D (accessed 4.25.24)."},{"key":"10.1016\/j.schres.2024.08.018_bb0015","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0957154X07070335","article-title":"The history of clozapine and its emergence in the US market: a review and analysis","volume":"18","author":"Crilly","year":"2007","journal-title":"Hist. Psychiatry"},{"key":"10.1016\/j.schres.2024.08.018_bb0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12916-018-1035-5","article-title":"Ethnic minority inequalities in access to treatments for schizophrenia and schizoaffective disorders: findings from a nationally representative cross-sectional study","volume":"16","author":"Das-Munshi","year":"2018","journal-title":"BMC Med."},{"key":"10.1016\/j.schres.2024.08.018_bb0025","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00127-022-02257-3","article-title":"Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical records","volume":"57","author":"de Freitas","year":"2022","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"10.1016\/j.schres.2024.08.018_bb0030","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/YIC.0000000000000108","article-title":"Maximizing clozapine utilization while minimizing blood dyscrasias: evaluation of patient demographics and severity of events","volume":"31","author":"Demler","year":"2016","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.08.018_bb0035","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.psc.2016.01.006","article-title":"Treatment-resistant schizophrenia","volume":"39","author":"Elkis","year":"2016","journal-title":"Psychiatric Clinics of North America, Schizophrenia: Advances and Current Management"},{"key":"10.1016\/j.schres.2024.08.018_bb0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1192\/bjb.2018.67","article-title":"Barriers to using clozapine in treatment-resistant schizophrenia: systematic review","volume":"43","author":"Farooq","year":"2019","journal-title":"BJPsych Bulletin"},{"key":"10.1016\/j.schres.2024.08.018_bb0045","doi-asserted-by":"crossref","unstructured":"Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4, J., Alhava, E., Olkinuora, M., Palva, I., 1975. Clozapine and agranulocytosis. The Lancet, Originally published as Volume 2, Issue 7935 306, 611. doi:https:\/\/doi.org\/10.1016\/S0140-6736(75)90206-8.","DOI":"10.1016\/S0140-6736(75)90206-8"},{"key":"10.1016\/j.schres.2024.08.018_bb0050","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12888-016-1167-0","article-title":"Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland","volume":"16","author":"Ingimarsson","year":"2016","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2024.08.018_bb0055","unstructured":"Johns Hopkins inHealth, 2024. https:\/\/www.hopkinsmedicine.org\/inhealth (accessed 5.5.24)."},{"key":"10.1016\/j.schres.2024.08.018_bb0060","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.4088\/JCP.v67n0911","article-title":"Clozapine utilization and outcomes by race in a public mental health system: 1994-2000","volume":"67","author":"Kelly","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2024.08.018_bb0065","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1176\/appi.ps.201700162","article-title":"Addressing barriers to clozapine underutilization: a national effort","volume":"69","author":"Kelly","year":"2018","journal-title":"PS"},{"key":"10.1016\/j.schres.2024.08.018_bb0070","article-title":"Clozapine and neutrophil response in patients of African descent: a six-month, multinational, prospective, open-label clinical trial","author":"Kelly","year":"2023","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.08.018_bb0075","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JCP.0000000000001606","article-title":"The modernization of clozapine: a recapitulation of the past in the United States and the view forward","volume":"42","author":"Leung","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.08.018_bb0080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/17512433.2023.2183192","article-title":"Improving clozapine utilization will require continued advocacy, drug sponsor interest, and FDA support to address REMS issues","volume":"16","author":"Leung","year":"2023","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2024.08.018_bb0085","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.4088\/JCP.15r10085","article-title":"Benign ethnic neutropenia and clozapine use: a systematic review of the evidence and treatment recommendations","volume":"77","author":"Manu","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2024.08.018_bb0090","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia\u2014an overview","volume":"77","author":"McCutcheon","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2024.08.018_bb0095","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.2020008600","article-title":"When non-Whiteness becomes a condition","volume":"137","author":"Merz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.schres.2024.08.018_bb0100","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/bloodadvances.2022007679","article-title":"Absolute neutrophil count by Duffy status among healthy Black and African American adults","volume":"7","author":"Merz","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.schres.2024.08.018_bb0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/acps.12898","article-title":"Meta-analysis examining the epidemiology of clozapine-associated neutropenia","volume":"138","author":"Myles","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2024.08.018_bb0110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2215-0366(23)00343-7","article-title":"Evaluating the epidemiology of clozapine-associated neutropenia among people on clozapine across Australia and Aotearoa New Zealand: a retrospective cohort study","volume":"11","author":"Northwood","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2024.08.018_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2018.08.016","article-title":"Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives","volume":"131","author":"Nucifora","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.schres.2024.08.018_bb0120","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.schres.2020.11.018","article-title":"Better functional capacity and cognitive performance in clozapine responders compared to non-responders: a cross-sectional study","volume":"229","author":"Nucifora","year":"2021","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.08.018_bb0125","doi-asserted-by":"crossref","DOI":"10.1017\/S204579602200066X","article-title":"Clozapine haematological monitoring for neutropenia: a global perspective","volume":"31","author":"Oloyede","year":"2022","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"10.1016\/j.schres.2024.08.018_bb0130","article-title":"Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case\u2013control study in Finland","volume":"0","author":"Rubio","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2024.08.018_bb0135","doi-asserted-by":"crossref","DOI":"10.1007\/s10597-023-01226-7","article-title":"Variation of clozapine use for treatment of schizophrenia: evidence from Pennsylvania Medicaid and dually eligible enrollees","author":"Sarpal","year":"2024","journal-title":"Community Ment. Health J."},{"key":"10.1016\/j.schres.2024.08.018_bb0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41537-022-00232-0","article-title":"Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis","volume":"8","author":"Taylor","year":"2022","journal-title":"Schizophrenia (Heidelb)"},{"key":"10.1016\/j.schres.2024.08.018_bb0145","series-title":"11-Year Follow-Up of Mortality in Patients with Schizophrenia: A Population-Based Cohort Study (FIN11 Study) 374","author":"Tiihonen","year":"2009"},{"key":"10.1016\/j.schres.2024.08.018_bb0150","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1017\/S0033291722001878","article-title":"Ethnic disparities in clozapine prescription for service-users with schizophrenia-spectrum disorders: a systematic review","volume":"52","author":"Ventura","year":"2022","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2024.08.018_bb0155","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.schres.2021.05.006","article-title":"Gender disparities in clozapine prescription in a cohort of treatment-resistant schizophrenia in the South London and Maudsley case register","volume":"232","author":"Wellesley Wesley","year":"2021","journal-title":"Schizophr. Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424003888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424003888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T08:58:42Z","timestamp":1740214722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996424003888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":31,"alternative-id":["S0920996424003888"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2024.08.018","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The timing and severity of clozapine-associated neutropenia in the US: Is the risk overstated?","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2024.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}